What Primacor (Lercanidipine) Treats: Main Uses and Benefits

Lercanidipine is commonly used for the long-term management of essential hypertension (high blood pressure) across adults. This therapeutic domain is relevant when patients exhibit mild-to-moderate blood pressure elevations, and the medication may be applied as either initial monotherapy or as part of a combination regimen when pressure is not adequately managed by other agents. This approach supports the goal of stabilizing sustained blood pressure readings.

The primary therapeutic focus is on conditions and symptoms related to systemic imbalance and heightened physiological activity. This supports the management of a fundamental health risk factor, which may include managing the risks associated with cardiovascular events, and the support of target organ protection in contexts such as those involving isolated systolic hypertension and co-existing diabetes mellitus. This medication helps address the symptom pattern of chronic asymptomatic blood pressure elevation and is relevant in contexts involving heightened systemic burden.

Quick Fact: Supports Management of Chronic Asymptomatic Blood Pressure Elevation

Eligibility for Primacor (Lercanidipin)

Primacor (lercanidipine) is a medication indicated for use in adults 18 years of age and older. Official regulatory documents define clear populations who must not use this medicine.

Classification	Populations / Conditions
Contraindicated	Hypersensitivity to lercanidipine or any dihydropyridine.
	Severe hepatic or severe renal impairment (GFR < 30 ml/min), including patients on dialysis.
	Certain heart conditions, including untreated congestive cardiac failure, left ventricular outflow tract obstruction, unstable angina, or within one month of a myocardial infarction.
	Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), ciclosporin, or grapefruit/grapefruit juice.

Not Recommended/Restricted	Populations
Pediatric Use	Children and adolescents under 18 years (safety and efficacy not established).
Pregnancy/Lactation	Pregnancy, lactation, or women of child-bearing potential not using effective contraception.
Organ Impairment	Mild to moderate renal or hepatic impairment (requires special care/caution).
Other	Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose/galactose malabsorption.

Special care is also recommended for initiating treatment in older adults.

Interactions with Other Medicines and Products

Lercanidipine is extensively metabolized by the CYP3A4 enzyme, which makes it susceptible to clinically significant drug interactions with inhibitors or inducers of this enzyme.

Contraindicated Combinations

Concomitant use with strong CYP3A4 inhibitors is contraindicated due to a large increase in lercanidipine plasma levels, which enhances its blood pressure-lowering effect. These inhibitors include certain:

• Antifungals (e.g., ketoconazole, itraconazole)
• Macrolide antibiotics (e.g., erythromycin, clarithromycin)
• Antivirals (e.g., ritonavir)

Also, the concurrent use of Ciclosporin (an immunosuppressant) and lercanidipine is not recommended as it leads to increased plasma levels of both drugs.

Other Significant Interactions

• CYP3A4 Inducers: Medicines that induce CYP3A4, such as certain anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital) and rifampicin, can reduce lercanidipine plasma levels, potentially diminishing its antihypertensive effect. Blood pressure should be closely monitored.
• Other Antihypertensives: Combining lercanidipine with other medicines that lower blood pressure, including beta-blockers (like metoprolol), may result in excessive reduction of blood pressure, sometimes requiring dose adjustment for lercanidipine.
• Digoxin: Caution is advised with patients taking digoxin, and they should be clinically monitored for signs of digoxin toxicity.
• Simvastatin: Lercanidipine may increase the plasma levels of Simvastatin; the drugs should be taken at different times of the day (lercanidipine in the morning, Simvastatin in the evening) to minimize interaction.

Food and Alcohol

Consumption of Grapefruit or grapefruit juice is contraindicated as it significantly increases the bioavailability of lercanidipine, leading to a stronger hypotensive effect. Alcohol should also be avoided as it can potentiate the effect of vasodilating antihypertensive drugs.

How Primacor (Lercanidipin) Works

Primacor, which contains lercanidipine, functions as a dihydropyridine calcium channel blocker. Its core mechanism involves binding to the L-type Ca^2+ channels

located on the membranes of vascular smooth muscle cells. This specific interaction results in the non-competitive blockade of the channel, thereby limiting the transmembrane influx of extracellular calcium ions into the cell. Calcium ion influx is an essential step in the excitation-contraction coupling process, triggering muscle fiber shortening.

By disrupting this key molecular cascade, lercanidipine directly promotes vascular smooth muscle relaxation. The resulting cellular effect is arterial vasodilation, which modulates local and systemic vascular tone. This physiological consequence leads to a reduction in peripheral vascular resistance. The drug exhibits a high degree of vascular tissue selectivity over myocardial tissue engagement and engages mechanisms that ensure a sustained interaction with the targeted channels.

General Administration Details for Primacor (Lercanidipine)

Lercanidipine hydrochloride is an oral medication supplied as a film-coated tablet, available in strengths of 10 mg and 20 mg. The protocol for administration is structured for the long-term, chronic management of the condition.

Instruction	Detail
Route of Administration	Oral use.
Dosing Schedule	The standard initial dose is 10 mg taken once daily. The dose may be gradually increased to the typical maintenance dose of 20 mg once daily. The maximum daily intake is limited to 20 mg.
Frequency and Timing	The medication is taken once daily. To ensure proper drug absorption, administration occurs at least 15 minutes before any meal, with the morning dose prior to breakfast being the preferred timing.
Handling and Constraints	The tablet is swallowed whole with water. Consumption of grapefruit or grapefruit juice is restricted due to its potential to affect the medicine’s concentration in the body.

Dose adjustments are carried out gradually, typically requiring a period of approximately two weeks to assess the stable effect of the drug after initiation or a dose change. For the older adult population, no mandatory adjustment to the daily dose is required, though care is advised when treatment is started. Lercanidipine is not recommended for use in the pediatric population (under 18 years) due to a lack of sufficient clinical data. If a once-daily dose is missed, the standard procedure is to skip the missed dose and resume the regular schedule; doubling the next dose is not appropriate.

Research Evidence / Overview of Studies for Primacor (Lercanidipin)

Evidence for Use in Essential Hypertension (High Blood Pressure)

Lercanidipine was studied for its application in the context of essential hypertension. Researchers primarily used short-term Randomized Controlled Trials (RCTs) to examine its effect. These trials often included evaluations against a placebo or against other established antihypertensive agents. The main outcomes documented in these short-term studies were measurements of Systolic and Diastolic blood pressure, and their measurements, over defined periods ranging from a few weeks to months.

Short-term RCTs reported patterns related to blood pressure measurements across the adult populations that were observed. Comparative trials also described patterns where the blood pressure measurements were documented alongside those seen with certain other calcium channel blockers and standard antihypertensive drugs. The results apply only to the populations studied, meaning the applicability to individuals with different types of hypertension or more severe conditions is not fully established by this evidence base.

---

Comparative Studies and Tolerability Profile

A significant part of the research involved studies where Lercanidipine was studied against other medications in the same class, specifically focusing on outcomes related to physical discomfort sometimes linked to blood vessel dilation. Researchers conducted comparative RCTs that focused on the incidence of events such as peripheral edema (ankle swelling).

Comparative studies reported on the incidence of peripheral edema and documented differences when compared against older-generation Dihydropyridine CCBs. The incidence of other events, such as headache and flushing, was also documented alongside other dihydropyridine agents. However, comparative evidence is lacking for Lercanidipine against every available newer therapeutic option.

---

Long-Term Studies and Extended Follow-up Data

Research into long-term health outcomes extends beyond the initial short-term RCTs. Studies observed the long-term patterns of use by leveraging observational studies and registry data over periods of several years. This type of research was designed to track Major Adverse Cardiovascular Events (MACE), including events like stroke and heart attack, in the populations who were observed during Lercanidipine use.

The long-term data relies heavily on observational studies, not prospective randomized trials, which means certainty remains low regarding conclusions about long-term cardiovascular outcomes based on the gold-standard of evidence. Long-term effects are not fully established through the highest quality of evidence.

Common questions about Primacor (Lercanidipin) (FAQ)

---

Q: Does Primacor treat high blood pressure itself, or just the symptoms?

According to official product information, Primacor is used for the long-term control and stabilization of chronic essential hypertension. Its mechanism is focused on modulating peripheral vascular resistance. By affecting this resistance, it addresses the underlying physiological process of high blood pressure, rather than being a mere symptomatic treatment.

---

Q: Does Lercanidipin treat other conditions besides high blood pressure?

Official regulatory documents state that Lercanidipin is indicated solely for the treatment of essential hypertension, which is high blood pressure with no known secondary cause. Its primary purpose in the adult population is the management of this chronic condition.

---

Q: Is this medicine used for heart problems other than hypertension?

Official documents restrict the use of Lercanidipin in patients with certain pre-existing heart conditions. These include untreated congestive heart failure, unstable angina, and use within one month after a heart attack. This indicates that it is not intended for the general treatment of a broad range of other heart problems.

---

Q: Why is Primacor often described as a selective calcium channel blocker?

The regulatory profile describes the medicine as having a high degree of vascular tissue selectivity. This means its main pharmacological effect is focused on the smooth muscles of the blood vessels (arteries) rather than primarily engaging the muscle tissue of the heart itself.

---

Q: How long do the effects of one Lercanidipin tablet typically last?

Regulatory documents indicate the half-life of the active substance in the plasma is typically 8 to 10 hours. The overall duration of its therapeutic action is designed to support convenient and effective once-daily dosing.

---

Q: Do I need to take Lercanidipin forever once my blood pressure is lowered?

The medicine is intended for the long-term management of chronic essential hypertension. This condition typically requires ongoing, consistent control to maintain blood pressure within a healthy range, according to regulatory indications for use.

---

Q: Why does Lercanidipin commonly cause swollen ankles (peripheral edema)?

Lercanidipin works by widening the arteries, a process called vasodilation. Official information describes that this mechanism is linked to the common occurrence of fluid accumulation, known as peripheral oedema or ankle swelling.

---

Q: Is feeling flushed a normal side effect of Primacor and how long does it last?

Yes, a flushed feeling (flushing) is listed as a common side effect in official safety profiles. Side effects related to the widening of blood vessels are generally described as transient, meaning they are temporary and often occur early in treatment.

---

Q: Why do people taking calcium channel blockers sometimes experience headaches?

The main function of this class of medicine is to cause arterial vasodilation, which is the widening of blood vessels. Headache is a common side effect documented in official data, which is widely understood to be linked to this blood vessel widening effect.

---

Q: What should I know about possible long-term side effects from Lercanidipin?

Regulatory data is primarily derived from trials of a defined period. Official assessment reports note that the long-term safety profile is under continuous observation, particularly regarding serious cardiovascular events.

---

Q: What is the difference in side effect profile between Lercanidipin and Amlodipine?

Official reports contain comparative data on the tolerability of Lercanidipine versus other dihydropyridine calcium channel blockers. These studies focused on differences in the incidence of vasodilatory-related events, such as peripheral oedema (ankle swelling).

---

Q: Does drinking alcohol increase the chance of side effects from Lercanidipin?

Official guidance states that alcohol is advised to be avoided because it can potentiate the effect of vasodilating antihypertensive drugs. This potentiation may lead to an increased likelihood of side effects, such as dizziness or excessively low blood pressure.

---

Q: What is the research on Lercanidipin use in patients with kidney function issues?

The medicine is contraindicated (not recommended for use) in patients with severe renal impairment (kidney function issues). For patients with mild to moderate kidney dysfunction, official warnings advise that special care and monitoring are needed upon initiation of treatment.

---

Q: How does the action of Lercanidipin differ from other calcium channel blockers, such as Nifedipine?

Lercanidipine is characterized as a third-generation calcium channel blocker. Comparative studies have documented patterns of efficacy and tolerability against older-generation dihydropyridine agents.

---

Q: How long does it usually take for Primacor to start affecting blood pressure?

The initial reduction in blood pressure is described as gradual. The official administration guidelines note that the full therapeutic effect is typically assessed after approximately two weeks of stable dosing.

---

Q: Is it normal to not feel any change when first starting this medicine?

Yes, this can be normal because the condition the medicine treats, essential hypertension, is frequently asymptomatic. The medicine is designed to control a measurement (blood pressure) and does not always cause a noticeable subjective change in a person's immediate feeling.

---

Q: Do the common side effects of Primacor usually go away after a few weeks?

The official product text describes vasodilatory side effects like flushing or headaches as transient and occurring early in treatment. While a specific timeline like 'a few weeks' is not guaranteed, this suggests the effects are typically not permanent.

---

Q: Is Lercanidipin known to cause hair loss or weight changes?

According to the official regulatory safety profile, events such as hair loss or weight changes are not listed in the documented adverse reactions by frequency (Common, Uncommon, or Rare).

---

Q: What does the official information say about Lercanidipin and effects on sexual function?

Adverse effects related to sexual function are not listed in the documented adverse reactions by frequency (Common, Uncommon, or Rare) found in the regulatory safety profile.

---

Q: What are the potential effects if I take Primacor with an anti-inflammatory drug (NSAID)?

The regulatory label notes that taking Primacor with anti-inflammatory drugs (NSAIDs), particularly when used chronically, may attenuate the antihypertensive effect. This means the NSAID could potentially lessen the blood pressure-lowering effect of Lercanidipin.

---

Q: Is there a known interaction between Lercanidipin and St. John's Wort?

Yes, official documents caution against co-administration with certain agents that induce the CYP3A4 enzyme. St. John's Wort is described as a CYP3A4 inducer that could potentially reduce the plasma levels of Lercanidipin, which may lower its effectiveness.

---

Q: Can taking Lercanidipin with a fatty meal increase the absorption of the medicine?

Official pharmacokinetic documents state that taking the medicine after a high-fat meal results in a significant increase in its plasma levels. Official guidance notes that the medicine should be administered before a meal, based on these findings.

---

Q: Does taking Primacor affect my ability to drive or operate machinery?

Official documents caution that the medicine may cause adverse reactions such as dizziness, weakness, or fatigue. If these effects occur, they could impair a person's ability to drive or safely operate machinery.

---

Q: Does this drug have any potential for misuse or dependency?

Official regulatory documents and assessment reports provide no information or indication that Lercanidipin has a potential for misuse or dependency.

---

Q: Why is Lercanidipin sometimes prescribed in combination with other blood pressure medicines?

The use of Lercanidipin in combination is described in regulatory guidelines for hypertension management. This strategy is used to achieve adequate blood pressure control in patients when a single therapeutic agent is considered insufficient.

Storage and Disposal Requirements for Primacor (Lercanidipine)

The official storage requirements for lercanidipine hydrochloride film-coated tablets are defined to ensure product stability and safety.

---

Storage Conditions

• Store the tablets at a temperature not exceeding 25^circC.
• Keep the medicine in its original package to ensure protection from moisture.
• The product must be kept out of the sight and reach of children.
• Do not use the medicine after the printed expiry date (EXP).

---

Disposal Instructions

Unused or expired Primacor must not be disposed of via wastewater or ordinary household waste.

To help protect the environment, the official instruction is to ask a pharmacist how to dispose of medicines that are no longer required.